Key result
Choline supplementation (75 μM) enhanced hepatocyte viability and reduced intracellular triglyceride content in NEFA-treated calf hepatocytes.
Why the study?
Perinatal dairy cows are susceptible to fatty liver syndrome, but the mechanisms driving the transition from physiological lipid storage to pathological steatosis remain incompletely understood.
Choline ameliorates NEFA-induced hepatic steatosis in an in vitro calf hepatocyte model by modulating the ROS/NF-κB-NLRP3-IL-1β/IL-18 signalling axis.
Answers are grounded in this paper and cite their sources.
Choline may mitigate NEFA-induced steatosis in vitro; hypothesis-generating for ruminant fatty liver and requires in vivo trials before any clinical consideration.
Perinatal dairy cows are highly susceptible to fatty liver syndrome, a prevalent metabolic disorder characterized by excessive hepatic lipid accumulation. Although inflammatory progression drives the transition from physiological lipid storage to pathological steatosis, the underlying mechanisms remain incompletely understood. This study investigates the therapeutic potential of choline in non-esterified fatty acid (NEFA)-induced hepatic inflammation and lipid metabolism dysregulation using an in vitro calf hepatocytes model. A hepatic steatosis model was established by treating primary calf hepatocytes with 1.2 mM NEFA for 24 h. Choline supplementation (75 μM) significantly enhanced hepatocyte viability and reduced intracellular triglyceride (TG) content (P < 0.05). Transcriptomic analysis demonstrated that choline downregulated key components of the NLRP3 inflammasome (P < 0.05) and interleukin-1β (IL-1β) expression (P < 0.05). Mechanistically, choline attenuated NF-κB phosphorylation (P < 0.05) and suppressed intracellular reactive oxygen species (ROS) generation (P < 0.05), thereby inhibiting NLRP3 inflammasome assembly and subsequent IL-1β maturation (P < 0.05). Notably, activation of NLRP3 inflammasome complete abolished choline's protective effects on lipid homeostasis and inflammatory responses (P < 0.05). These findings demonstrate that choline ameliorates NEFA-induced hepatic steatosis by modulating the ROS/NF-κB-NLRP3-IL-1β/IL-18 signalling axis, providing novel therapeutic targets for intervention of steatohepatitis in periparturient dairy cows.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied Hepatic steatosis. Choline vs. NEFA alone was evaluated on Hepatocyte viability and intracellular triglyceride (TG) content (p=< 0.05). Choline supplementation (75 μM) enhanced hepatocyte viability and reduced intracellular triglyceride content in NEFA-treated calf hepatocytes.
Synapse has enriched 10 related papers. Consider them for comparative context: